Search Results - "Wcisło, G."

Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines by Bodnar, L., Stec, R., Cierniak, S., Synowiec, A., Wcisło, G., Jesiotr, M., Koktysz, R., Kozłowski, W., Szczylik, C.

“…The aim of this study was to search for predictive and prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus among…”
Get full text

979P - Predictive and Prognostic Role of Survivin and P53 Expression in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy by Bodnar, A. Gasowska, Bodnar, L., Jerzak, M., Wcisło, G., Cichowicz, M., Da˛bek, A., Kozłowski, W., Szczylik, C., Baranowski, W.

“…Qualification of patients with advanced ovarian cancer (AOC) to treatment with primary or interval debulking surgery (IDS) is the subject of controversy. The…”
Get full text

Predictive and Prognostic Role of Survivin and P53 Expression in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy by Bodnar, A. Gasowska, Bodnar, L., Jerzak, M., Wcisło, G., Cichowicz, M., Da˛bek, A., Kozłowski, W., Szczylik, C., Baranowski, W.

Get full text

Serum TRAIL levels in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. A pilot study by Gasowska-Bodnar, A, Bodnar, L, Synowiec, A, Jerzak, M, Wcislo, G, Smoter, M, Szczylik, C, Baranowski, W

“…The study attempted to evaluate the kinetics of changes in serum TRAIL levels as a potential predictive and prognostic factor in patients with epithelial…”
Get more information

5035 POSTER A protective role of magnesium salt supplementation against anaemia induced by paclitaxel and cisplatin in ovarian cancer (OC) patients by Bodnar, L, Wcislo, G, Synowiec, A, Cieslak, A, Szczylik, C

Get full text

Pleural effusion in cancer patients:pathophysiology, diagnosis and treatment by Wcisło, G, Miedzińska, M

“…Pleural effusion is a clinical problem considered by internists from the diagnostic point of view. Physiology of pleural cavity and its pathophysiology are of…”
Get more information

Nephroprotective role of magnesium salt in cisplatin-induced renal damage in patients with ovarian cancer by Wcislo, G., Bodnar, L., Szczylik, C.

“…Abstract only…”
Get full text

Cystatin C, an additional marker of ovarian cancer extent: A pilot study by Wcislo, G., Bodnar, L., Szarlej-Wcislo, K., Gasowska-Bodnar, A., Szczylik, C.

“…Abstract only 16080 Background: Cystatin C is a cysteine protease inhibitor which has been recommended as the marker of glomerular filtration rate (GFR). We…”
Get full text

Topotecan therapy as salvage in heavily pretreated ovarian cancer patients (hpocp) by Wcislo, G. B., Bodnar, L., Nasilowska, A., Szarlej-Wcislo, K., Szczylik, C.

“…Abstract only 15057 Background: Topotecan is utilized as to a second-line chemotherapy agent in ovarian cancer. The third or more line of chemotherapy is…”
Get full text

Salvage therapy with topotecan (topo) of heavily pretreated ovarian cancer patients (hpocp) by Wcislo, G. B., Bodnar, L., Miedzinska-Maciejewska, M., Szczylik, C.

“…Abstract only…”
Get full text

Salvage therapy with topotecan (topo) of heavily pretreated ovarian cancer patients (hpocp) by Wcislo, G. B., Bodnar, L., Miedzinska-Maciejewska, M., Szczylik, C.

“…Abstract only…”
Get full text

Local treatment with tumor necrosis factor alpha in a patient with lung cancer by Chciałowski, A, Płusa, T, Szczylik, C, Mamełka, B, Bajera, I, Targowski, T, Dudko, S, Wcisło, G

“…Tumor Necrosis Factor alfa (TNFa) is a cytokine with cytolytic and cytotoxic properties. First clinical trials in which TNF was administered parenterally date…”
Get more information

171. Chemioterapia dotętnicza metodą BOLUS z zastosowaniem 5-FU przerzutów raka jelita grubego do wątroby. Badanie fazy II by Korniluk, J., Wcisło, G., Brzozowski, K., Nurzyński, P., Osiecki, M., Barzał, J., Twarkowski, P., Szczylik, C.

“…Chemioterapia dotętnicza (HAI-th)jest leczeniem paliatywnym przerzutów do wątroby w raku jelita grubego (r.j.g). W badaniu dokonano oceny efektywności i…”
Get full text